Pantoprazole - Takeda
Alternative Names: Anagastra; B-8610-23; BY-1023; Controloc; DZ-2352A; Eupantol; Inipomp; Pangest; Pantecta; Pantoloc; Pantop; Pantopan; Pantozol; Peptazol; Protium; Protonix; Rifun; SKF 96022; Somac; Tecta; Tecta Control; Ulcotenal; ZacPac; ZurcalLatest Information Update: 05 Nov 2023
At a glance
- Originator Nycomed
- Developer Pfizer; Takeda Pharmaceuticals International GmbH
- Class 2 pyridinylmethylsulfinylbenzimidazoles; Antiulcers; Gastric antisecretories; Small molecules
- Mechanism of Action Proton pump inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Duodenal ulcer; Erosive oesophagitis; Gastric ulcer; Gastritis; Gastro-oesophageal reflux; Heartburn; Helicobacter infections; Peptic ulcer; Zollinger-Ellison syndrome
- No development reported Pancreatitis
Most Recent Events
- 15 Oct 2021 Phase-II clinical trials in Erosive oesophagitis (In children, In adolescents, In infants) in Slovakia, Belgium, Hungary (PO) (EudraCT2020-005030-15)
- 29 Mar 2021 Pfizer plans a phase II trial for Erosive oesophagitis (In infants, In adolescent, In children) (PO) (NCT04821310) (EudraCT2020-005030-15)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Pancreatitis in Germany